Sugi Predict

Sugi Predict / Compounds / SCHEMBL2809688

SCHEMBL2809688

SCHEMBL2809688

CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)C[C@H]1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.37
▸ NR1H2 P55055 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ HTRA1 Q92743 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ MCL1 Q07820 2/20 0.33
▸ BCL2 P10415 1/20 0.32
▸ BCL2L1 Q07817 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ PPM1D O15297 1/20 0.31
▸ HSD11B1 P28845 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239646 1.00 UCHL1 (0.39) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL3832206 1.00 UCHL1 (0.39) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL2708045 1.00 UCHL1 (0.39) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL29203075 1.00 UCHL1 (0.39) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL18577100 1.00 UCHL1 (0.39) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL3832181 1.00 UCHL1 (0.39) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL9020470 0.90 UCHL1 (0.34) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL4300617 0.89 UCHL1 (0.37) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL4300613 0.89 UCHL1 (0.37) UCHL1HSD17B10NR1H2CYP1A2POLB
SCHEMBL29548437 0.89 UCHL1 (0.37) UCHL1HSD17B10NR1H2CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120025395-A C-3 substituted pentacyclic triterpenoid benzylamide derivative and preparation method and application thereof 惠州卫生职业技术学院 2025-05-23 — — CN disclosed
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 — — EP disclosed
CN-119497712-A Indane derivatives as MALT1 inhibitors 希四克斯探索有限公司 2025-02-21 — — CN disclosed
US-20250026734-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2025-01-23 — — US disclosed
WO-2024237331-A1 CHOLINE SALT OF PHENANTHRIDINONE DERIVATIVE オンコリスバイオファーマ株式会社 2024-11-21 — — WO disclosed
EP-4434969-A1 ANTI-SARS-COV-2 DRUG Oncolys BioPharma, Inc. (JP) 2024-09-25 — — EP disclosed
US-20240254140-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2024-08-01 — — US disclosed
EP-4405352-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2024-07-31 — — EP disclosed
EP-4405353-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2024-07-31 — — EP disclosed
CN-117980303-A Novel compounds and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-05-03 — — CN disclosed
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2018-03-15 — — US disclosed
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2018-03-15 — — US disclosed
EP-3275440-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME National Center for Geriatrics and Gerontology (JP) 2018-01-31 — — EP disclosed
US-20100240638-A1 Organic Compounds and their uses NOVARTIS AG (CH) 2010-09-23 — — US disclosed
US-20100240638-A1 Organic Compounds and their uses NOVARTIS AG (CH) 2010-09-23 — — US disclosed
EP-2125757-A1 MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS Novartis AG (CH) 2009-12-02 — — EP disclosed
WO-2008101665-A1 MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS NOVARTIS AG (CH) 2008-08-28 — — WO disclosed
EP-0545290-B1 Aminoalkylpyrrolidinylthiocarbapenem derivatives BANYU PHARMA CO LTD (JP) 2000-08-23 — — EP disclosed
US-5550121-A ANTIBIOTICS BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-08-27 — — US disclosed
EP-0545290-A1 Aminoalkylpyrrolidinylthiocarbapenem derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-06-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026734-A1 ANTI-SARS-COV-2 DRUG ACE2, SARS1, ACE UCHL1 3435/4885HSD17B10 343/4885NR1H2 255/4885
US-20100240638-A1 Organic Compounds and their uses OAT, HAVCR2, CYP3A43 UCHL1 233/4885HSD17B10 310/4885NR1H2 381/4885
US-20240254140-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION C3AR1, LTB4R, C5 UCHL1 4090/4885HSD17B10 2015/4885NR1H2 1206/4885
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME APP, BACE1, PSEN1 UCHL1 726/4885HSD17B10 1066/4885NR1H2 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.